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OBJECTIVES This study intended to assess the role of mitochondrial ATP-sensitive potassium (mitoKATP)
channels and the sequence of signal transduction with protein kinase C (PKC) and adenosine
A1 receptors in rabbits.
BACKGROUND To our knowledge, the link between trigger receptors of preconditioning, PKC and mitoKATP
channels has not been examined in a whole heart model of infarction.
METHODS In the first series of experiments, myocardial infarction was induced in isolated buffer-
perfused rabbit hearts by 30-min global ischemia and 2-h reperfusion. Infarct size in the left
ventricle was determined by tetrazolium staining and expressed as a percentage of area at risk
(i.e., the whole left ventricle) (%IS/AR). In the second series of experiments, mitochondria
were isolated from the heart, and their respiratory function was examined using glutamate as
a substrate.
RESULTS Pretreatment with R-phenylisopropyladenosine (R-PIA, 1 mmol/liter), an A1-receptor ago-
nist, reduced %IS/AR from 49.8 6 6.5% to 13.4 6 2.9%. This protection was abolished by
calphostin C, a PKC inhibitor, and by 5-hydroxydecanoate (5-HD), a selective inhibitor of
mitoKATP channels. A selective mitoKATP channel opener, diazoxide (100 mmol/liter),
mimicked the effect of R-PIA on infarct size (%IS/AR 5 11.6 6 4.0%), and this protective
effect was also abolished by 5-HD. However, calphostin C failed to block the infarct
size–limiting effect of diazoxide. Neither calphostin C nor 5-HD alone modified %IS/AR.
State III respiration (QO2) and respiratory control index (RCI) were reduced after 30 min of
ischemia (QO2 5 147.3 6 5.3 vs. 108.5 6 12.3, RCI 5 22.3 6 1.1 vs. 12.1 6 1.8, p , 0.05).
This mitochondrial dysfunction was persistent after 10 min of reperfusion (QO2 5 96.1 6
15.5, RCI 5 9.5 6 1.9). Diazoxide significantly attenuated the respiratory dysfunction after
30 min of ischemia (QO2 5 142.8 6 9.7, RCI 5 16.2 6 0.8) and subsequent 10-min
reperfusion (QO2 5 135.3 6 7.2, RCI 5 19.1 6 0.8).
CONCLUSIONS These results suggest that mitoKATP channels are downstream of PKC in the mechanism of
infarct-size limitation by A1-receptor activation and that the anti-infarct tolerance afforded by
opening of mitoKATP channels is associated with preservation of mitochondrial function
during ischemia/reperfusion. (J Am Coll Cardiol 1999;35:238–45) © 1999 by the American
College of Cardiology
Exposing the myocardium to brief transient ischemia para-
doxically enhances its tolerance against subsequent ischemia
insult. The mechanism of this phenomenon, termed “isch-
emic preconditioning,” has been a subject of intense inves-
tigation for a decade (1,2). Studies to date indicate that the
preconditioning mechanism is triggered by activation of
several classes of receptors, including adenosine and brady-
kinin receptors, which transmit signals to protein kinase C
(PKC) and perhaps subsequent kinase cascades (1–3). How-
ever, the effector at the end of the signal transduction that is
responsible for myocardial tolerance against ischemic cell
death still has not been clarified. One possibility is ATP-
sensitive potassium channel (KATP) channels. Gross and
Auchampach (4) first found that preconditioning protection
is abolished by KATP channel inhibitors and mimicked by
KATP channel openers, suggesting the involvement of this
channel in preconditioning. This possibility was further
supported by patch-clamp experiments showing that acti-
vation of this channel in sarcolemma is induced by adeno-
sine A1 receptor (5) and PKC (6). However, shortening of
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the action potential duration by either preconditioning (7)
or a KATP channel opener (8) did not correlate with the
cardioprotection afforded by these manipulations, arguing
against the possibility that KATP channels in the sarcolemma
are relevant to preconditioning protection. However, mito-
chondrial ATP-sensitive potassium channels (mitoKATPs)
channels, which are in the inner membrane of the mito-
chondria (9), have received attention as a possible effector of
preconditioning, since the opening of mitoKATP channels
appears to be PKC-regulated (10) and cardioprotective
against ischemic insult (11,12). In a recent study by Liu et
al. (12), diazoxide, a KATP channel opener, reversibly oxi-
dized flavoproteins in the mitochondria of isolated cardio-
myoytes, and this oxidation was inhibited by a selective
mitoKATP channel blocker, 5-hydroxydecanoate (5-HD)
(10,13), indicating that the flavoprotein oxidation is due to
opening of mitoKATP channels. Furthermore, diazoxide
significantly delayed cardiomyocyte death during 120 min of
simulated ischemia, suggesting anti-infarct tolerance af-
forded by mitoKATP channel opening (12).
However, to our knowledge, the link between trigger
receptors of preconditioning (such as A1 receptors), PKC
and mitoKATP channels has not been examined in a whole-
heart model of infarction. It is also unknown whether
changes in mitochondrial function by opening of mitoKATP
channels during ischemia/reperfusion contribute to infarct-
size limitation by preconditioning. Accordingly, in the
present study, we first compared an A1-receptor agonist
(R-phenylisopropyladenosine [R-PIA]) with diazoxide in
regard to infarct size–limiting effects and alteration of their
cardioprotective effects by a PKC inhibitor (calphostin C)
and a mitoKATP channel blocker (5-HD). If the mitoKATP
channel is an effector downstream of PKC in the anti-
infarct mechanism triggered by A1-receptor stimulation,
both R-PIA and diazoxide should similarly limit infarct size,
and their effects should be abolished by 5-HD. Further-
more, the effect of R-PIA, but not that of diazoxide, should
be prevented by calphostin C. In the second series of
experiments, the effects of diazoxide on mitochondrial
dysfunction after ischemia and reperfusion were examined
to get an insight into the role of mitochondrial function in
mitoKATP channel-mediated cardioprotection.
METHODS
Experiment 1: Role of mitoKATP and PKC in Infarct Size
Limitation by Preischemic A1-Receptor Stimulation
Isolated rabbit heart preparation. Male albino rabbits
(Japanese White), weighing 2.0 to 2.5 kg, were anesthetized
by pentobarbital (30 mg/kg IV), underwent tracheostomies
and were ventilated by a respirator (Harvard model 683).
The chest was opened by left thoracotomy, and the heart
was quickly excised and mounted on a nonrecirculating
Langendorff apparatus with a water jacket. Before the heart
excision, 2,000 U of heparin was injected intravenously to
prevent thrombosis in the coronary arteries. The heart was
perfused with a modified Krebs-Henseleit buffer at 37°C
(NaCl, 118.5 mmol/liter; KCl, 4.7 mmol/liter; NaHCO3,
24.8 mmol/liter; KH2CO3, 1.2 mmol/liter; MgSO4,
1.2 mmol/liter; CaCl2, 2.5 mmol/liter; glucose, 10.0 mmol/
liter), which was continuously oxygenated by 95% O2 and
5% CO2. A 3F catheter tip manometer (SPR-524, Millar
Instruments Inc., Houston, Texas) was inserted into the left
ventricle via the left atrium to monitor ventricular pressure,
and coronary flow was measured by collection of coronary
effluent in a graduated cylinder. The heart was excluded
from the study if the left ventricular systolic pressure was
,70 mm Hg or arrhythmias were observed after a 15-min
stabilization period.
Experimental protocol. After stabilization, all of the
hearts underwent 30-min of global ischemia and 2-h reper-
fusion. To maintain myocardial temperature at 37°C during
global ischemia, the temperature of the water circulating in
the water jacket of the heart chamber was raised to 38°C,
and the chamber was sealed with a thick plastic film during
the ischemic period. Prior to global ischemia, each heart was
subjected to one of the following nine treatments: no drug
(untreated controls), diazoxide, 5-HD, diazoxide plus
5-HD, calphostin C, diazoxide plus calphostin C, R-PIA,
R-PIA plus calphostin C and R-PIA plus 5-HD. Diazoxide
(100 mmol/liter), 5-HD (30 mmol/liter) and R-PIA
(1 mmol/liter) were infused for 10 min before the onset of
ischemia. Calphostin C (200 nmol) was administered for
8 min before ischemia. The Krebs-Henseleit buffer contain-
ing these pharmacologic agents was kept in a reservoir
separate from the main reservoir containing normal buffer.
Since global no-flow ischemia was induced by clamping a
perfusion line to the aorta, the pharmacologic agents stayed
in the myocardium during the ischemic period. After 2 h of
reperfusion, the heart was removed from the perfusion
apparatus, weighed after removal of the atria, and frozen at
220°C.
Determination of infarct size. Infarct size was determined
by the same method as that used in our previous studies
(3,14). In brief, frozen hearts were sliced in parallel to the
Abbreviations and Acronyms
5-HD 5 5-hydroxydecanoate
%IS/AR 5 infarct size as a percentage of area
at risk
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AV groove into approximately 2-mm sections and then
incubated in 100 mmol/liter sodium phosphate buffer
(pH 5 7.4) containing 1% triphenyltetrazolium for 20 min
at 237°C to visualize infarcts. The heart slices were
mounted on a glass press, which compressed the slices
uniformly to exactly 2 mm in thickness. A clear acetate sheet
was overlaid on the glass press, and the outlines of the LV
and infarcted area were traced on the acetate sheet. The
traces were read by a computer (Macintosh Quadra 840AV)
using a scanner (Hewlett Packard ScanJetIIC), and their
areas were measured by NIH image, an image analysis
software. The areas of infarct and the LV were multiplied by
the thickness of the heart slice to obtain their volumes.
Experiment 2: Effect of Diazoxide on
Mitochondrial Dysfunction After Ischemia and Reperfusion
Isolated rabbit heart preparation and experimental pro-
tocol. Isolated rabbit hearts were prepared and perfused as
in experiment 1. Each heart was subjected either to no drug
treatment or to 100 mmol/liter diazoxide for 10 min and
rendered ischemic by clamping the perfusion line above the
aorta. The left ventricular myocardium was sampled for
mitochondria isolation at the end of 30-min ischemia or
after 10 min of reperfusion following the 30-min ischemia.
Myocardial samples from nonischemic hearts served as
controls.
Isolation of mitochondria. Mitochondria were isolated
from the ventricular sample according to the method of
Vercesi et al. (15) with some modification. The sample
(about 1.5 g) was weighed, washed and quickly minced with
scissors in 5 ml of isolation buffer (180 mmol/liter KCl,
10 mmol/liter EDTA.2K, 0.5% bovine serum albumin in
10 mmol/liter Tris-HCl buffer, pH 5 7.4) containing 0.1%
nargarse at 4°C. The minced sample was resuspended in a
10-part volume of isolation buffer and homogenized by a
Potter-type homogenizer. The homogenate was centrifuged
at 600 g for 5 min to obtain the supernatant. The superna-
tant was centrifuged at 10,000 g for 10 min, and the
sediment obtained was washed and suspended in isolation
buffer without nargarse. The suspension was recentrifuged
at 10,000 g for 5 min to obtain the final mitochondrial
pellet. The pellet was suspended in 150 ml of isolation buffer
and used immediately for experiments to determine the
respiratory function of mitochondria. Protein concentration
in the mitochondria sample was determined using a BCA
Protein Assay Kit (PIERCE, Rockford, Illinois).
Determination of mitochondrial respiration. Mitochon-
drial respiration was measured at 25°C by an oxygen
monitor (UC-12 Digital DO/O2/Temp Meter, Central
Science, Japan), which polarographically determines oxygen
concentration in a water-jacketed sample chamber (vol-
ume 5 1.2 ml). The assay medium (3 mmol/liter K2HPO4,
1 mmol/liter EDTA.2K, 250 mmol/liter sucrose in
10 mmol/liter Tris-HCl buffer, pH 5 7.4) was pre-
equilibrated with air at 25°C before being transferred into
the sample chamber. A mitochondrial sample (30 or 50 ml)
was added to the assay medium in the chamber, and then
10 mmol/liter glutamate was added as a substrate. After
state II respiration was recorded for 2 min, state III
respiration was initiated by addition of 500 nmol of ADP.
The respiratory control index (RCI) and ADP/O ratio were
calculated by the method of Chance and Williams (16).
Experiment 3: Effect of
Diazoxide on Isolated Mitochondria
Rabbit hearts were perfused without ischemia, and mito-
chondria were isolated from the ventricular myocardium as
in Experiment 2. The mitochondria suspension was divided
into two parts: one for experiments using an assay medium
containing 100 mmol/liter diazoxide and the other for the
experiments using a medium containing vehicle (0.1%
dimethylsulfoxide) alone. Diazoxide or the vehicle was
added to the assay medium immediately before use. Mito-
chondrial respiratory function was determined as in Exper-
iment 2.
Chemicals. Diazoxide, calphostin C, ADP and bovine
albumin were purchased from (SIGMA), St. Louis, Mis-
souri), and 5-HD and R-PIA were obtained from another
company (Research Biochemical Institute, Natick, Massa-
chusetts). Nargase was also purchased from another com-
pany (Boehringer Ingelheim Bioproducts, Heidelberg, Ger-
many).
Statistical analysis. Differences in infarct size, hemody-
namic parameters and mitochondrial function among the
study groups were tested by one-way analysis of variance.
When the overall difference was significant in analysis of
variance, an intergroup comparison was performed by the
Student-Newman-Keul post-hoc test. The unpaired t test
was used to compare mitochondrial function in the diazox-
ide medium with that in vehicle medium (Experiment 3).
The difference was considered significant at p , 0.05. All
data are expressed as mean value 6 standard error of the
mean.
RESULTS
Experiment 1. Effects of R-PIA, Diazoxide, Calphostin
C and 5-HD on Infarct Size in Isolated Rabbit Hearts
Hemodynamic data. Heart rate, left ventricular developed
pressure (LVDP) and coronary flow are summarized in
Table 1. Under baseline conditions, there were no signifi-
cant differences in the hemodynamic parameters among all
of the study groups. R-PIA reduced the heart rate by 30%
and increased coronary flow by approximately 20%, while
LVDP was not significantly changed. This coronary vaso-
dilation by R-PIA, an A1 agonist, can be explained by the
large A2 receptor reserve in the coronary artery (17).
Diazoxide increased coronary flow by 40% without signifi-
cant change in heart rate and LVDP. Calphostin C slightly
increased the coronary flow, but 5-HD had no effect on the
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hemodynamic parameters. The effects of diazoxide and
R-PIA on coronary flow or heart rate were not abolished by
coadministration of either 5-HD or calphostin C. At 2 h
after reperfusion, LVDP in the diazoxide-treated hearts was
significantly higher than that in the controls; however, all
other differences in heart rate, LVDP, and coronary flow
between controls and any of the drug-treated groups did not
reach statistical significance.
Infarct size data. Infarct size and size of area at risk (i.e.,
LV mass) are summarized in Table 2. There was no
significant difference in the size of area at risk among the
study groups. R-PIA reduced infarct size as a percentage of
area at risk (%IS/AR) from 49.8 6 6.5 to 13.4 6 2.9.
Neither 5-HD nor calphostin C alone modified infarct size.
However, this infarct size–limiting effect of R-PIA was not
observed when calphostin C or 5-HD was added to the
Table 1. Summary of Hemodynamic Data in Experiment 1
Treatment n Baseline After Tx Reperfusion
Heart rate (beats/min)
Control 9 235 6 4 226 6 4 205 6 8
R-PIA 6 226 6 11 152 6 17* 188 6 9
R-PIA 1 calphostin C 6 240 6 12 156 6 15* 186 6 15
R-PIA 1 5-HD 7 210 6 13 137 6 9* 181 6 16
Diazoxide 9 232 6 8 225 6 9 176 6 17
Diazoxide 1 calphostin C 6 214 6 3 207 6 3 165 6 8
Diazoxide 1 5-HD 7 231 6 7 223 6 6 172 6 16
Calphostin C 7 245 6 13 225 6 13 171 6 15
5-HD 7 221 6 6 210 6 8 178 6 8
LVDP (mm Hg)
Control 9 83 6 3 83 6 4 29 6 5
R-PIA 6 81 6 2 86 6 4 39 6 4
R-PIA 1 calphostin C 6 87 6 5 84 6 7 21 6 15
R-PIA 1 5-HD 7 83 6 3 86 6 4 18 6 6
Diazoxide 9 82 6 1 81 6 3 58 6 5*
Diazoxide 1 calphostin C 6 86 6 4 85 6 8 52 6 8
Diazoxide 1 5-HD 7 77 6 1 75 6 2 32 6 11
Calphostin C 7 79 6 1 79 6 2 38 6 3
5-HD 7 80 6 2 74 6 2 25 6 4
Coronary flow (ml/min)
Control 9 54 6 2 54 6 2 25 6 4
R-PIA 6 62 6 4 75 6 5* 35 6 4
R-PIA 1 calphostin C 6 62 6 2 79 6 5* 30 6 3
R-PIA 1 5-HD 7 68 6 3 80 6 3* 25 6 3
Diazoxide 9 52 6 4 76 6 3* 33 6 2
Diazoxide 1 calphostin C 6 67 6 5 81 6 6* 37 6 3
Diazoxide 1 5-HD 7 65 6 5 84 6 9* 27 6 5
Calphostin C 7 64 6 5 72 6 6* 33 6 4
5-HD 7 59 6 5 59 6 5 27 6 3
After Tx 5 after treatment; reperfusion 5 2 h after the onset of reperfusion. R-PIA 5 R-phenylisopropyladenosine; 5-HD 5
5-hydroxydecanoate.
Mean 6 SE, *p , 0.05 vs. control.
Table 2. Summary of Infarct Size Data in Experiment 1
Treatment n Area at Risk, cm3 Infarct, cm3 %IS/AR
Control 9 2.81 6 0.16 1.46 6 0.25 49.8 6 6.5
R-PIA 6 2.69 6 0.17 0.37 6 0.10* 13.4 6 2.9*
R-PIA 1 calphostin C 6 2.58 6 0.08 1.40 6 0.11 54.1 6 4.2
R-PIA 1 5-HD 7 2.66 6 0.11 1.58 6 0.23 59.8 6 8.5
Diazoxide 9 2.38 6 0.11 0.29 6 0.11* 11.6 6 4.0*
Diazoxide 1 calphostin C 6 2.23 6 0.11 0.31 6 0.17* 12.8 6 6.8*
Diazoxide 1 5-HD 7 2.78 6 0.13 1.27 6 0.21 45.2 6 6.7
Calphostin C 7 2.27 6 0.11 0.94 6 0.11 41.7 6 4.1
5-HD 7 2.75 6 0.18 1.69 6 0.22 60.5 6 5.0
%IS/AR 5 infarct size as a percentage of area at risk; R-PIA 5 R-phenylisopropyladenosine; 5-HD 5 5-hydroxydecanoate.
Mean 6 SEM, *p , 0.05 vs. control.
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pretreatment regimen. Diazoxide achieved infarct-size lim-
itation (%IS/AR 5 11.6 6 4.0), the extent of which was
comparable to that by R-PIA. In contrast with the effect of
R-PIA, the effect of diazoxide on infarct size was not
abolished by calphostin C, although 5-HD blocked
diazoxide-induced infarct size–limitation.
Experiment 2: Mitochondrial Respiratory
Function After Ischemia and Reperfusion:
Diazoxide-Treated Hearts Versus Untreated Hearts
Table 3 summarizes the data of mitochondrial function after
ischemia/reperfusion. The ADP/O ratio was not changed
after 30-min ischemia and after 10-min reperfusion. How-
ever, the rate of oxygen consumption in state III respiration
(QO2) and RCI were reduced after ischemia (from 147.3 6
5.3 to 108.5 6 12.3 and from 22.3 6 1.1 to 12.1 6 1.8,
respectively, both p , 0.05). Both QO2 and RCI remained
suppressed at 10 min after reperfusion. However, when the
heart was pretreated with 100 mmol/liter diazoxide, the
reduction of QO2 and RCI by ischemia was significantly
attenuated, and RCI recovered almost to the control level
after 10 min of reperfusion.
Experiment 3. Effects of Diazoxide on
Respiratory Functions of Isolated Mitochondria
As shown in Table 4, when 100 mmol/liter diazoxide was
included in the assay buffer, the ADP/O ratio and QO2 were
similar, but RCI was significantly lower compared with RCI
in the normal assay buffer (19.1 6 0.9 vs. 15.3 6 1.3, p ,
0.05). Since RCI is the ratio of QO2 to state IV respiration,
this reduction of RCI indicates acceleration of state IV
respiration by diazoxide in vitro.
DISCUSSION
The present study demonstrated that 100 mmol/liter of
diazoxide preserved mitochondrial functions after ischemia/
reperfusion and reduced infarct size by 75%. This infarct
size–limiting effect of diazoxide was comparable to that of
1 mmol/liter of R-PIA, an A1-receptor agonist, and the
cardioprotective effects of both agents were abolished by
5-HD. However, calphostin C blocked the infarct-size
limitation by R-PIA but not that by diazoxide. These results
support the hypothesis that signals triggered by an A1
receptor are transmitted via a PKC-mediated pathway to
mitoKATP channels and that the opening of these channels
plays a crucial role in preservation of mitochondrial function
and cell viability during ischemia.
Doses of diazoxide and 5-HD to examine the function of
mitoKATP channels. A recent study by Garlid et al. (11)
showed that mitoKATP channels have a unique phar-
macologic profile. The EC50 for diazoxide to activate
mitoKATP channels in reconstituted mitoKATP channels is
estimated to be approximately 0.8 mmol/liter, while
.1 mmol/liter of diazoxide is necessary to open sarcolem-
mal KATP channels (11). Our results show that 100 mmol/
liter diazoxide significantly reduced RCI with insignificant
change in QO2 (Table 4), which is consistent with reduction
of inner membrane potential by opening of mitoKATP
channels. The dose of diazoxide used in the present study
was sufficient to activate smooth muscle type KATP channels
(18), causing a 40% increase in coronary flow (Table 1).
However, this vasodilatory effect of diazoxide is unlikely to
be essential to the cardioprotection, because the increase in
coronary flow during diazoxide infusion was not antago-
nized by 5-HD, which, however, abolished the infarct
size–limiting effect of diazoxide.






Control 10 2.49 6 0.13 147.3 6 5.3 22.3 6 1.1 3.1 6 0.2
Ischemia 7 2.50 6 0.11 108.5 6 12.3* 12.1 6 1.8* 3.5 6 0.2
Ischemia/reperfusion 7 2.39 6 0.13 96.1 6 15.5* 9.5 6 1.9* 3.6 6 0.2
Diazoxide 1 ischemia 8 2.63 6 0.06 142.8 6 9.7 16.2 6 0.8* 3.4 6 0.2
Diazoxide 1 ischemia/reperfusion 8 2.73 6 0.07 135.3 6 7.2 19.1 6 0.8 3.2 6 0.2
ADP/O 5 ADP/O ratio; QO2 5 state III respiration; RCI 5 respiratory control index.
Mean 6 SE, *p , 0.05 vs. control.




Control 11 2.63 6 0.04 149.1 6 9.9 19.1 6 0.9
Diazoxide, 100 mmol/liter 11 2.64 6 0.03 133.2 6 9.1 15.3 6 1.3*
ADP/O 5 ADP/O ratio; QO2 5 state III respiration; RCI 5 respiratory control index.
Mean 6 SE, *p , 0.05 vs. control.
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The dose of 5-HD used in the present study
(30 mmol/liter) is rather low compared with the doses
employed for blocking mitoKATP channels in earlier studies
(11,12). The EC50 of 5-HD to block mitoKATP channels,
which were opened by diazoxide, in the reconstituted rat
heart mitochondria was around 83 mmol/liter (11). Thus,
30 mmol/liter of 5-HD appears rather low, but this dose of
5-HD blocked the infarct size–limiting effects of diazoxide
and R-PIA in isolated rabbit hearts (Table 2). Actually,
100 mmol/liter of 5-HD alone appeared to enlarge infarct
size in our preliminary experiments. The reason for this
apparent contradiction is not clear, but a possible explana-
tion is the difference in temperature during experiments.
Although the EC50 of 5-HD was obtained by experiments
performed at 25°C in the earlier study (11), our infarct-size
experiments were conducted at 37°C, at which the EC50 of
5-HD could be lower. Most recently, Liu et al. (13) found
that 100 mmol/liter of 5-HD selectively blocked the open-
ing of mitoKATP channels, without inhibiting the response
of sarcolemmal KATP channels, to pinacidil in the rabbit
cardiomyocytes. Thus, the present dose of 5-HD appears
appropriate to selectively assess the functions of mitoKATP
channels in isolated heart preparations.
Relationship among adenosine receptors, PKC and
mitoKATP channels. A number of earlier studies (19–22)
have demonstrated that activation of A1 receptors markedly
enhances myocardial tolerance against ischemic injury. Al-
though most of the evidence for PKC activation by aden-
osine receptor stimulation in cardiomyocytes is rather cir-
cumstantial, it was demonstrated that A1 receptor
stimulation activates phospholipase C-b and phospholipase
D (20,23,24), both of which produce diacylglycerol, an
activator of PKC. In cultured human pediatric myocytes, a
relatively high dose of adenosine (i.e., 50 mmol/liter) in-
creased PKC activity by threefold (22). Furthermore, several
pharmacologic findings have indicated that PKC has an
important role in adenosine-induced cardioprotection. In a
previous study, we found that PKC inhibitors (staurospor-
ine and polymyxin B) completely abolished infarct size
limitation by R-PIA in the rabbit heart in situ (14). The
present study confirmed this previous observation in isolated
hearts using a more selective PKC inhibitor, calphostin C
(25). The inhibitory effect of PKC inhibitors on anti-infarct
tolerance was recently characterized also in isolated cardio-
myocyte preparations. Although the optimal dose of aden-
osine receptor agonists varies depending on the preparations
(i.e., human pediatric cardiomyocytes, chick embryo ven-
tricular myocytes and adult rabbit ventricular myocytes),
adenosine and A1 agonists prevented ischemic myocyte
death, and such protection was abolished by chelerythrine
and calphostin C (19,22,26). Furthermore, two lines of
evidence indicate a link between PKC and KATP channels in
infarct size–limitation. First, PKC-activating phorbol esters
facilitate the opening of sarcolemmal KATP channels (6) and
mitoKATP channels (10). Second, delay of ischemic myocyte
death by A1-receptor agonists and a PKC-activating phor-
bol was prevented by glibenclamide (21,26). Poor selectivity
of glibenclamide (11) does not allow differentiation of the
roles of sarcolemmal KATP and mitoKATP channels in these
earlier observations. However, a finding that 5-HD at a
mitoKATP channel selective dose completely inhibited car-
dioprotection by R-PIA (Table 2) and a report that ischemic
preconditioning (27) was abolished by 5-HD suggest that
the mitoKATP channel is a major effector in anti-infarct
tolerance.
The present study demonstrated that infarct size was
limited to 25% of the control value by diazoxide, which is
consistent with recent findings by Baines et al. (28) in the in
situ rabbit heart. As shown in Table 2, the extent of
infarct-size reduction by diazoxide is comparable with that
achieved by 1 mmol/liter of R-PIA, and the cardioprotective
effects of both agents were similarly abolished by 5-HD.
These results further support the role of mitoKATP channels
in infarct size–limitation by A1-receptor activation. Fur-
thermore, considering the failure of calphostin C to block
diazoxide-induced cardioprotection, it is likely that opening
of mitoKATP channels occurs downstream of PKC activa-
tion in the mechanism of infarct size–limitation by preisch-
emic A1-receptor activation.
In contrast, activation of PKC subsequent to mitoKATP
channel opening is suggested as a mechanism of cardiopro-
tection against calcium paradox in a study by Wang and
Ashraf (29). In their study, diazoxide reduced myocardial
necrosis by calcium paradox, and this protective effect of
diazoxide was abolished by 5-HD and also by chelerythrine,
a PKC inhibitor. However, these findings are not necessar-
ily contraditory to the present result of calphostin C,
because mechanisms of myocyte destruction are quite dif-
ferent for calcium paradox and ischemia/reperfusion. Sepa-
ration of the fascia and macula adherens junctions is a
crucial initial step for myocyte destruction by calcium
paradox (30), while Na1-H1 exchange is unlikely to be an
important mechanism of calcium overload in this phenom-
enon (31). In contrast, activation of Na1-H1 exchange
significantly contributes to myocardial necrosis during isch-
emia/reperfusion (32), presumably through acceleration of
Na1-Ca11 exchange, and the change in fascia adherens
junctions in ischemic myocytes appears after irreversible
changes in the mitochondria (33,34). Thus, although dia-
zoxide is protective against both ischemia/reperfusion and
calcium paradox, the sequence of signals and cell protective
effectors may be different in these two types of insults.
Protection of mitochondria from ischemic injury by
diazoxide. It is not clear how the opening of mitoKATP
channels enhances the tolerance of myocytes to lethal
ischemic injury. The function of mitoKATP channels is
thought to regulate mitochondrial volume and thermo-
genesis (35,36), both of which are apparently unrelated to
ischemic injury. The opening of mitoKATP channels
would lower transmembrane potential and thus reduce
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efficiency of ATP production. Indeed, Portenhauser et al.
(37) observed that 400 mmol/liter diazoxide suppressed
state III respiration by 22%, and RCI by 44%, in isolated
rat mitochondria. In the present experiments, probably
because of the lower concentration (i.e., 100 mmol/liter),
reduction in RCI by diazoxide was modest, and the
change in state III respiration was statistically insignifi-
cant. This reduction in RCI per se does not appear to be
clearly beneficial for ischemic cardiomyocytes. Further-
more, a recent study by Holmuhamedov et al. (38)
suggests that a high dose of KATP channel openers can
even be detrimental to mitochondrial function and struc-
ture. They showed that incubation of isolated mitochon-
drial with 250 mmol/liter pinacidil or 100 mmol/liter
cromakalim caused release of cytochrome c and adenylate
kinase, two important proteins in the intermembrane
space. Thus, the effect of mitoKATP channel opening on
mitochondrial injury during ischemia is probably depen-
dent on the degree of their opening activity. Neverthe-
less, the present study showed that pretreatment with
100 mmol/liter diazoxide was effective in preserving
mitochondrial function during and after 30 min of
ischemia (Table 3) and in limiting myocardial necrosis
(Table 2).
The effects of diazoxide on mitochondria during isch-
emia/perfusion (Table 3) are quite compatible with the
reported effects of ischemic preconditioning (39–41). Three
earlier studies (39–41) consistently showed that ischemic
preconditioning preserves mitochondrial function and pre-
vents loss of adenine nucleotide translocase activity during
ischemia/reperfusion. However, whether the preservation of
mitochondrial function is a part of cardioprotective mech-
anisms or a result of myocyte protection remains unclear.
The contribution of mitochondrial damage to myocardial
infarction has been studied for more than a decade, but
there is no strong evidence supporting the possibility that a
certain degree of reduced mitochondrial function deter-
mines the transition from reversible to irreversible myocyte
injury (34). Rather, ATP production by mitochondria
during ischemia would be theoretically the same, and
negligible, regardless of the functional status of mitochon-
dria, because lack of oxygen limits oxidative phosphoryla-
tion. However, there is a possibility that mitochondrial
function preserved by diazoxide and preconditioning may
support energy production in critically injured myocytes at
the time of reperfusion, which otherwise fail to survive the
subsequent reperfusion period.
Conclusions. The present data indicate that the opening
of mitoKATP channels is downstream of PKC activation
in the mechanism of infarct size limitation by adenosine
A1-receptor stimulation. How mitoKATP channel open-
ing enhances anti-infarct tolerance of the cardiomyocytes
remains unclear, but preservation of the functional ca-
pacity of mitochondria during ischemia/reperfusion may
be involved.
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